Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.80 |
| ▸ | DRD3 | P35462 | 3/20 | 0.65 |
| ▸ | DRD2 | P14416 | 2/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.61 |
| ▸ | HRH1 | P35367 | 2/20 | 0.61 |
| ▸ | HTR2B | P41595 | 2/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7245981 | 0.92 | DRD3 (0.68) | APAF1DRD3DRD2HTR2AHRH1 | |
| SCHEMBL11604609 | 0.90 | APAF1 (0.98) | APAF1DRD3DRD2HTR2AHRH1 | |
| SCHEMBL3034533 | 0.86 | APAF1 (0.84) | APAF1DRD3DRD2HTR2AHRH1 | |
| Hydrochloric Acid SCHEMBL11846883 | 0.85 | APAF1 (0.85) | APAF1DRD3DRD2SIGMAR1HDAC1 | |
| SCHEMBL12868327 | 0.84 | APAF1 (0.79) | APAF1DRD3DRD2HTR2AHRH1 | |
| Biriperone SCHEMBL635469 | 0.79 | DRD3 (1.00) | APAF1DRD3SIGMAR1 | |
| SCHEMBL7147206 | 0.78 | DRD2 (0.65) | APAF1DRD3DRD2HTR2AHRH1 | |
| SCHEMBL7647981 | 0.76 | HTR1A (1.00) | DRD3DRD2HTR2AHRH1HTR2B | |
| SCHEMBL11181604 | 0.76 | APAF1 (0.62) | APAF1DRD3DRD2HTR2AHRH1 | |
| SCHEMBL7140346 | 0.76 | CDK4 (0.52) | APAF1DRD3SIGMAR1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075974-A1 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS | UMN PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090075974-A1 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS | UMN PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1140934-B1 | BENZISOXAZOLES AND PHENONES AS ALPHA-2-ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2003-10-08 | — | — | EP | disclosed |
| US-6576640-B1 | Rapidly penetration into central nervous system; treating noradrenaline deficiency; depression, Parkinson's disease | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-06-10 | — | — | US | disclosed |
| EP-1140934-A1 | BENZISOXAZOLES AND PHENONES AS $g(a) 2?-ANTAGONISTS | Janssen Pharmaceutica N.V. (BE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037466-A1 | BENZISOXAZOLES AND PHENONES AS α2-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075974-A1 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS | HTR2A, HTR2B, HTR2C | APAF1 861/4885DRD3 517/4885DRD2 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.